ACR 2022 Tweet by Mike Putman
Tweet
Related Content
Professor van Vollenhoven has compiled a state-of-the-art review on lupus treatment advances – current and future. SLE management is entering an unprecedented phase.
An economic evaluation of early vs delayed use of the Blys inhibitor, belimumab (BEL), in systemic lupus erythematosus (SLE) has shown both cost effectiveness and clinical utility of early BEL initiation in active lupus patients.While most would advocate for using your best therapy first when…
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.Early vs Delayed Belimumab in Lupus An economic evaluation of early vs delayed use of the Blys inhibitor, belimumab (BEL), in systemic lupus erythematosus (SLE) has shown both cost-effectiveness and clinical…
